No critical observation by UK health regulator: Wockhardt

By: |
New Delhi | Published: September 29, 2016 1:29:49 PM

Drug firm Wockhardt today said that the UK health regulator has completed inspection of its Chikalthana plant at Aurangabad in Maharashtra without making any critical observations.

gen-reu-LThe UK regulator had in October 2013 withdrawn the GMP certificate to the Chikalthana plant and had also initiated recall of five prescription medicines from there. (Source: Reuters)

Drug firm Wockhardt today said that the UK health regulator has completed inspection of its Chikalthana plant at Aurangabad in Maharashtra without making any critical observations.

“The inspection of our manufacturing unit at L-1, Chikalthana, Aurangabad, Maharashtra by UK MHRA has since been completed without any critical observations and the approval status of the said unit continues,” Wockhardt said in a filing to BSE today.

It further said: “The said audit was as per schedule.”

The UK regulator had in October 2013 withdrawn the GMP certificate to the Chikalthana plant and had also initiated recall of five prescription medicines from there.

In December 2015, Wockhardt received a good manufacturing practice (GMP) certificate from the UK health regulator for its Chikalthana plant after an inspection.

Shares of Wockhardt were trading at Rs 926.50 per scrip on BSE, up 2.28 per cent, from its previous close.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition